Irbesarran en es it fr

Irbesarran Brand names, Irbesarran Analogs

Irbesarran Brand Names Mixture

  • Avalide 150/12.5 mg (Hydrochlorothiazide + Irbesartan)
  • Avalide 300/12.5 mg (Hydrochlorothiazide + Irbesartan)

Irbesarran Chemical_Formula


Irbesarran RX_link

Irbesarran fda sheet

Irbesarran FDA

Irbesarran msds (material safety sheet)

Irbesarran MSDS

Irbesarran Synthesis Reference

C. Bernhart et al.; U.S. Pat. 5,270,317 (1993)

Irbesarran Molecular Weight

428.53 g/mol

Irbesarran Melting Point

180-181 oC

Irbesarran H2O Solubility

No information avaliable

Irbesarran State


Irbesarran LogP


Irbesarran Dosage Forms

Tablet (oral)

Irbesarran Indication

For the treatment of hypertension, and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension.

Irbesarran Pharmacology

Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.

Irbesarran Absorption

Rapid and complete with an average absolute bioavailability of 60-80%. Food has no affect on bioavailability.

Irbesarran side effects and Toxicity

Hypotension and tachycardia; bradycardia might also occur from overdose, LD50=mg/kg(orally in rat)

Irbesarran Patient Information

Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to drugs that act on the renin-angiotensin system, and they should also be told that these consequences do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

Irbesarran Organisms Affected

Humans and other mammals